Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Target Price at $77.67

Corcept Therapeutics Incorporated (NASDAQ:CORT) has been given an average rating of “Moderate Buy” by the eight analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $77.6667.

CORT has been the subject of a number of recent research reports. Zacks Research lowered Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. HC Wainwright reduced their price target on Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, March 25th. UBS Group initiated coverage on Corcept Therapeutics in a research report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price objective for the company. Canaccord Genuity Group increased their price objective on Corcept Therapeutics from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel for platinum‑resistant ovarian cancer is a material commercial catalyst that triggered the earlier sharp rally; approval creates a new revenue pathway and is the primary reason investors re‑rated the stock this week. FDA approval report
• Positive Sentiment: Broker/analyst support: Wolfe Research upgraded CORT (from underperform to peer‑perform) and other brokers (Truist, Canaccord) have issued bullish/strong‑buy views or raised targets, which can sustain buying interest as the market models new sales upside. Wolfe Research upgrade
• Neutral Sentiment: Market structure/volatility: trading halts and large intraday prints accompanied the approval-driven move — expect continued high volume and price swings as investors reprice expectations for launch and uptake. Market reaction coverage
• Neutral Sentiment: Consensus/ratings mix: some outlets show a “moderate buy” brokerage consensus; analysts remain mixed on valuation as the market weighs launch potential vs. prior execution and study data. Broker consensus report
• Negative Sentiment: Legal risk: multiple law firms have filed shareholder alerts and class actions alleging that Corcept misled investors about regulatory issues and patent matters; these suits (and the referenced FDA rejection / federal court patent loss claims) create potential liability, discovery risk and distraction for management. Hagens Berman class‑action alert
• Negative Sentiment: Insider selling: a recent disclosed sale by an insider reduced holdings significantly; while not proof of negative outlook, such sales can weigh on sentiment when paired with litigation headlines. Insider sale filing
• Negative Sentiment: Analyst divergence / forecast cuts: some firms have tempered long‑term estimates or issued cautious notes (e.g., a pessimistic forecast from HC Wainwright in recent coverage), underscoring uncertainty around peak sales and reimbursement. HC Wainwright coverage

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 11,767 shares of the firm’s stock in a transaction on Friday, March 20th. The shares were sold at an average price of $36.01, for a total value of $423,729.67. Following the sale, the insider owned 2,231 shares of the company’s stock, valued at $80,338.31. This trade represents a 84.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director G Leonard Baker, Jr. acquired 100,000 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was purchased at an average price of $33.14 per share, for a total transaction of $3,314,000.00. Following the transaction, the director directly owned 1,146,631 shares of the company’s stock, valued at approximately $37,999,351.34. This trade represents a 9.55% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold 86,198 shares of company stock valued at $3,552,769 in the last quarter. Company insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Abacus FCF Advisors LLC bought a new position in Corcept Therapeutics in the 3rd quarter worth $3,238,000. JPMorgan Chase & Co. boosted its stake in shares of Corcept Therapeutics by 223.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company’s stock valued at $70,632,000 after purchasing an additional 587,053 shares in the last quarter. Pacer Advisors Inc. increased its position in shares of Corcept Therapeutics by 6,796.7% during the third quarter. Pacer Advisors Inc. now owns 390,559 shares of the biotechnology company’s stock valued at $32,459,000 after buying an additional 384,896 shares during the period. Brown Capital Management LLC purchased a new position in shares of Corcept Therapeutics during the third quarter valued at about $19,950,000. Finally, Cerity Partners LLC raised its stake in Corcept Therapeutics by 21.4% in the second quarter. Cerity Partners LLC now owns 746,593 shares of the biotechnology company’s stock worth $54,800,000 after buying an additional 131,799 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Price Performance

CORT stock opened at $37.60 on Friday. The firm has a market cap of $4.00 billion, a P/E ratio of 45.85 and a beta of 0.29. The firm’s fifty day moving average is $37.53 and its 200 day moving average is $60.61. Corcept Therapeutics has a 52 week low of $28.66 and a 52 week high of $117.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The business had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. During the same period in the prior year, the firm earned $0.26 earnings per share. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. Research analysts predict that Corcept Therapeutics will post 1.36 earnings per share for the current year.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.